




# APEX Phase 2 Part A readout

EADV Update


# Zumilokibart APEX Part A demonstrated rapid, deep itch relief

## Zumilokibart (APG777) Part A: Itch Numerical Rating Scale (I-NRS)



**Zumilokibart demonstrated rapid itch relief similar to NEMLUVIO + TCS**

- Zumilokibart<sup>2</sup>
- EBGLYSS<sup>4</sup>
- DUPIXENT<sup>3</sup>
- NEMLUVIO+TCS<sup>5</sup>



NOTE: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. Daily change in I-NRS in Week 1 was evaluated as-observed without imputation for missing data. Weekly I-NRS based on non-responder imputation for rescue medication (topical or systemic) use or treatment discontinuation due to lack of efficacy (i.e., data subsequent to the use of rescue medication or discontinuation due to lack of efficacy are categorized as non-response). Statistical treatment of missing data varies across studies shown. Zumilokibart vs placebo: \*p<0.05, \*\*<0.01, \*\*\*p<0.001. LS = Least squares. <sup>1</sup>Based on Daily I-NRS score. <sup>2</sup>Placebo rate at hour 48 for zumilokibart = -4.2 (N=41). <sup>3</sup>DUPIXENT hour 48 I-NRS based on digitized pooled SOLO 1&2 data for 300mg Q2W (N=457) vs. placebo (N=460). SOURCE: Silverberg, JI et al. J. Am Acad. Dermatol. (2020). <sup>4</sup>EBGLYSS hour 48 I-NRS based on digitized pooled ADvocate 1&2 data for 250mg Q4W (N=564) vs. placebo (N=287). SOURCE: Yosipovitch, G et al, BJD (2023). <sup>5</sup>NEMLUVIO hour 48 I-NRS based on digitized plot for 30 mg Q4W (N=50) vs placebo (N=44); mixed model for repeated measures for missing values SOURCE: Silverberg, JI et al J. EADV 2021, Ph2b.